Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

469
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
469
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

749
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
749

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Curricular Content Reduction on Student-Reported Mental and Physical Health.

American journal of pharmaceutical education·2025
Same author

Knowledge of Kratom among Alabama Pharmacists.

Pharmacy (Basel, Switzerland)·2024
Same author

Effect of Interprofessional Clinical Debates on Attitudes of Interprofessional Teams.

PRiMER (Leawood, Kan.)·2021
Same author

EZ-Root-VIS: A Software Pipeline for the Rapid Analysis and Visual Reconstruction of Root System Architecture.

Plant physiology·2018
Same author

Overview of venous thromboembolism.

The American journal of managed care·2018
Same author

Implementation and Assessment of an Ambulatory Prescribing Guidance Tool to Improve Patient Safety in the Geriatric Population.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2017

Related Experiment Video

Updated: May 1, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

392

Thrombophilia Screening.

Lori B Hornsby1, Emily M Armstrong2, Jessica M Bellone3

  • 1Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Auburn, AL, USA Midtown Medical Center, Columbus, GA, USA hornslb@auburn.edu.

Journal of Pharmacy Practice
|April 18, 2014
PubMed
Summary
This summary is machine-generated.

Screening for thrombophilia is often debated. Current evidence suggests routine testing for most inherited clotting disorders offers limited benefit in guiding treatment for venous thromboembolism (VTE).

Keywords:
antiphospholipid antibodiesantithrombin deficiencyfactor V Leideninherited thrombophiliaprotein C deficiencyprotein S deficiencyprothrombin mutationscreeningthrombophilia

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

174
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K

Related Experiment Videos

Last Updated: May 1, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

392
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

174
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K

Area of Science:

  • Hematology
  • Clinical Medicine
  • Diagnostic Testing

Background:

  • Thrombophilia screening is increasingly common, despite ongoing debate regarding its clinical utility.
  • Antiphospholipid antibodies are indicated for antiphospholipid syndrome diagnosis and treatment guidance.
  • The value of identifying other thrombophilias in symptomatic venous thromboembolism (VTE) is questionable.

Purpose of the Study:

  • To evaluate the utility of thrombophilia screening in patients with venous thromboembolism (VTE).
  • To assess the impact of thrombophilia status on recurrence risk and treatment decisions.
  • To review current guidelines regarding thrombophilia testing in various clinical scenarios.

Main Methods:

  • Review of current literature and clinical guidelines on thrombophilia testing.
  • Analysis of the association between thrombophilia status and VTE recurrence risk.
  • Evaluation of cost-effectiveness and clinical impact of screening in specific populations.

Main Results:

  • Most common thrombophilias (Factor V Leiden heterozygosity, prothrombin gene mutation) do not significantly increase VTE recurrence risk.
  • Increased recurrence risk may be associated with homozygous or multiple thrombophilias and natural anticoagulant deficiencies, but these are rare.
  • Current guidelines suggest anticoagulation duration should be based on event characteristics, not thrombophilia status.
  • Routine prophylaxis or screening in asymptomatic individuals or prior to oral contraceptive use is not recommended.

Conclusions:

  • Routine thrombophilia screening in most symptomatic VTE patients is not well-justified due to limited impact on recurrence risk and treatment decisions.
  • Screening asymptomatic family members or before prescribing oral contraceptives is generally not cost-effective or clinically beneficial.
  • Treatment decisions for VTE should primarily focus on clinical factors like event location and provoking agents, rather than thrombophilia status.